China's Global Leadership in Pancreatic Cancer: A 2024-2026 Deep Dive
Between 2024 and 2026, China’s pancreatic cancer treatment landscape underwent a fundamental shift. The country moved from following international guidelines to setting new benchmarks — in surgical volume, survival rates, drug development, and AI-assisted diagnosis. This report summarizes the key breakthroughs.
1. Heavy Ion Radiation Therapy: Breaking the Monopoly
Heavy ion therapy — the most advanced form of radiation treatment — delivers precise radiation with maximum tumor damage and minimal harm to surrounding tissues. It was previously monopolized by a few countries (Japan, Germany, Italy, USA).
China’s breakthrough: The Wuwei Heavy Ion Center in Gansu Province became China’s first clinical application site for domestically developed heavy ion therapy, operational since 2020 and treating patients for 5+ years. The system was fully developed by the Chinese Academy of Sciences’ Institute of Modern Physics — making China the 4th country to master this technology.
2025 expansion: Zhejiang Province’s Heavy Ion Medical Center opened in February 2025 with China’s first self-developed device reaching international advanced standards, further expanding access.
2. Robotic Surgery: #2 Globally
Ruijin Hospital’s Pancreatic Disease Center has completed 4,000+ Da Vinci robotic pancreatic surgeries (2,000+ for malignant tumors) — ranking #1 in China and #2 globally, behind only the University of Pittsburgh Medical Center.
Starting in 2025, Ruijin hosts monthly international robotic surgery training workshops, sharing techniques with surgeons worldwide.
Domestic surgical robot companies are also accelerating: Shurui completed a $100M Series D in December 2025, and Jingfeng’s bronchial robot received NMPA approval in January 2025.
3. NanoKnife (Irreversible Electroporation) Ablation
NanoKnife technology creates nanoscale pores in tumor cell membranes using high-voltage electrical pulses — destroying cancer cells while preserving blood vessels and nerves. It’s particularly valuable for pancreatic tumors that wrap around major vessels.
May 2026 milestone: China’s Venna Medical received NMPA Class III registration for its domestically developed “Venna Knife” — with approved indications for both liver cancer and pancreatic cancer. The device enables local anesthesia procedures, significantly reducing treatment costs (50% less than imported equipment).
4. AI-Assisted Diagnosis: FDA Breakthrough
Alibaba’s DAMO PANDA became the first AI model to receive FDA “Breakthrough Medical Device” designation for pancreatic cancer screening. Key metrics:
- Sensitivity: 92.9%
- Specificity: 99.9%
- Works on routine (non-contrast) CT scans
- Can detect pancreatic cancer years before symptoms
The WHO promoted this technology globally at the 2024 AI for Good Summit in Geneva.
5. Five-Year Survival: 21.2% vs. Global 9-12%
Ruijin Hospital reported a 21.2% five-year overall survival rate for pancreatic cancer — nearly double the global average. For Stage I patients: 35.3%. These results, accumulated over 30,000+ cases, have earned recognition from Heidelberg University, the American Pancreas Society, and the French Academy of Medicine as establishing China as a “new center” in global pancreatic cancer treatment.
6. ESMO Asia-Pacific Consensus: China’s Voice
Prof. Shen Baiyong of Ruijin Hospital became the only Chinese expert to co-author the Pancreatic Cancer Systemic Therapy Asia-Pacific Expert Consensus published in ESMO Gastrointestinal Oncology. This consensus adapts international standards to Asian patient characteristics — addressing gaps where Western guidelines don’t fully account for regional drug availability and patient profiles.
7. Drug Development Pipeline
KRAS Inhibitors
- GFH375 (GenFleet): World’s first oral KRAS G12D inhibitor to enter Phase III. ORR 41%, DCR 97% in heavily pretreated PDAC. NDA planned for 2027.
- D3S-001: New-generation KRAS G12C inhibitor proven effective across lung, colorectal, and pancreatic cancers.
Antibody-Drug Conjugates (ADCs)
- IBI343 (Innovent): CLDN18.2 ADC for pancreatic cancer. ORR 22.7%, DCR 81.8%. Breakthrough Therapy designation from CDE.
- LM-302 (LaNova): CLDN18.2 ADC. Twice received Breakthrough Therapy designation. Global leader in development speed.
Bispecific Antibodies
- Cadonilimab (Akeso): PD-1/CTLA-4 bispecific antibody. Combined with chemotherapy, achieved mOS 23.4 months in locally advanced pancreatic cancer — a milestone result presented at AACR 2026.
- TQB2868 (Chia Tai Tianqing): PD-1/TGF-β fusion protein. First-in-class to enter Phase III for pancreatic cancer globally. Combined therapy showed ORR 63.9%, DCR 100%.
mRNA Vaccines
- KRAS G12V mRNA Vaccine (Ruijin): World’s first report in Cell Research (IF 28.1). First patient achieved 31% tumor reduction, 27-month survival. Now in Phase I.
8. Precision Diagnostics: China’s First Pancreatic Cancer Gene Panel
Prof. Yu Xianjun’s team at Fudan Cancer Center developed the world’s first in-vitro diagnostic kit specifically for pancreatic cancer — a 6-gene mutation panel that passed Shanghai Drug Administration registration in December 2025. The 2025 Chinese Expert Consensus on Precision Detection and Molecular Diagnosis standardized NGS-based molecular profiling for all pancreatic cancer patients.
9. Integrated MDT Model
China’s pancreatic cancer centers have evolved beyond single-discipline treatment:
- Multi-disciplinary tumor boards as standard practice
- “Gene ID Card” approach — molecular profiling guides every treatment decision
- 12-dimensional risk assessment model for population screening
- AI-driven treatment planning integrating multi-omics data
Conclusion: From “Running Behind” to “Running Ahead”
The data is clear: China has moved from following international pancreatic cancer treatment standards to influencing them. The combination of massive surgical volume (30,000+ cases at Ruijin alone), breakthrough survival rates (21.2%), world-first drug approvals, and AI-assisted screening positions Shanghai — and China broadly — as a genuine global center for pancreatic cancer treatment.
The question for international patients is no longer “is China capable?” but “what’s the best way to access this capability?”
Deep research report compiled from 68+ verified sources including Nature, Cell Research, ESMO, AACR, NCCN, FDA, WHO, and Chinese hospital disclosures. Last updated: May 2026. This article does not constitute medical advice.